Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 380
- Registration Number
- NCT04423861
- Locations
- 🇧🇷
Hospital Vera Cruz, Campinas, São Paulo, Brazil
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 42
- Registration Number
- NCT04352465
- Locations
- 🇧🇷
Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 50
- Registration Number
- NCT04348409
- Locations
- 🇧🇷
Hospital Vera Cruz, Campinas, São Paulo, Brazil
🇧🇷Centro de Genomas, São Paulo, Brazil
🇧🇷Hospital Emílio Ribas, São Paulo, Brazil
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
- Conditions
- Covid-19
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 200
- Registration Number
- NCT04348474
- Locations
- 🇧🇷
Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 400
- Registration Number
- NCT04329572
- Locations
- 🇧🇷
Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
- Conditions
- COVID-19 Pneumonia
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 90
- Registration Number
- NCT04315987
- Locations
- 🇧🇷
Hospital Vera Cruz, Campinas, São Paulo, Brazil
🇧🇷Hospital de Barueri, São Paulo, Brazil
🇧🇷IncCOR, São Paulo, Brazil
Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.
- Conditions
- Huntington Disease
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 35
- Registration Number
- NCT04219241
- Locations
- 🇧🇷
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 40
- Registration Number
- NCT03572647
- Locations
- 🇧🇷
LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
- Conditions
- Huntington Disease
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 35
- Registration Number
- NCT03252535
- Locations
- 🇧🇷
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
- Conditions
- Huntington Disease
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 6
- Registration Number
- NCT02728115
- Locations
- 🇧🇷
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil